RxDoctor Payments Data

Margaret Tsai, MD

Internal Medicine · Lorain, OHNPI 1114146693

Payments from drug & device makers

$14,500in general payments, 2019–2025

Across 61 payments — averaging $237.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Cardinal Health 108 LLC$3K
  • Lilly USA, LLC$2K
  • UCB, Inc.$1K
  • Amgen$928
  • Pfizer$359
  • plus $743 from 7 others

What the payments were for

  • Consulting fees$5,48838%
  • Speaking & faculty fees$5,10035%
  • Travel & lodging$1,1028%
  • Food & beverage$2,80019%
  • Education$100%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie12$6,215
Cardinal Health 108 LLC9$2,599
Lilly USA, LLC2$2,332
UCB, Inc.3$1,324
Amgen(2 entities)15$928
Pfizer10$359
Novartis3$201
GSK2$111
Genentech USA, Inc.1$111
Medtronic1$105
Cardinal Health 110 LLC1$100
Mallinckrodt Enterprises LLC1$94
GRT US Holding, Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,500 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$77,263
Medicare patients
526
Services billed
1,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab257$2,105,835
Enbrel SureclickEtanercept79$621,364
XeljanzTofacitinib Citrate66$376,988
Xeljanz XrTofacitinib Citrate60$358,907
OrenciaAbatacept58$322,843
RinvoqUpadacitinib42$279,168
Enbrel MiniEtanercept22$257,024
Cosentyx Sensoready (2 Pens)Secukinumab26$229,784
EnbrelEtanercept25$227,013
ActemraTocilizumab31$143,207
Humira PenAdalimumab11$141,586
ForteoTeriparatide31$125,178
Actemra ActpenTocilizumab17$110,666
KevzaraSarilumab26$106,790
Humira(Cf)Adalimumab13$89,899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$359$376,98866 claims
AbbVieRinvoq, Humira(Cf)$6,215$369,06755 claims
AmgenEnbrel, Otezla$928$299,17041 claims
Lilly USA, LLCForteo$2,332$125,17831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Lorain

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →